These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28161993)

  • 1. Eribulin in non-small cell lung cancer: challenges and potential strategies.
    Swami U; Shah U; Goel S
    Expert Opin Investig Drugs; 2017 Apr; 26(4):495-508. PubMed ID: 28161993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
    O'Sullivan Coyne G; Walsh J; Kelly CM
    Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin in Cancer Treatment.
    Swami U; Shah U; Goel S
    Mar Drugs; 2015 Aug; 13(8):5016-58. PubMed ID: 26262627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
    Gitlitz BJ; Tsao-Wei DD; Groshen S; Davies A; Koczywas M; Belani CP; Argiris A; Ramalingam S; Vokes EE; Edelman M; Hoffman P; Ballas MS; Liu SV; Gandara DR
    J Thorac Oncol; 2012 Mar; 7(3):574-8. PubMed ID: 22198425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.
    Seetharam M; Kolla KR; Chawla SP
    Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of eribulin for the treatment of metastatic breast cancer.
    Perez-Garcia JM; Cortes J
    Expert Opin Drug Saf; 2019 May; 18(5):347-355. PubMed ID: 31107111
    [No Abstract]   [Full Text] [Related]  

  • 10. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
    Polastro L; Aftimos PG; Awada A
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
    Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
    J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
    Katakami N; Felip E; Spigel DR; Kim JH; Olivo M; Guo M; Nokihara H; Yang JC; Iannotti N; Satouchi M; Barlesi F
    Ann Oncol; 2017 Sep; 28(9):2241-2247. PubMed ID: 28911085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
    Aseyev O; Ribeiro JM; Cardoso F
    Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin: a novel cytotoxic chemotherapy agent.
    Preston JN; Trivedi MV
    Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin -- a review of preclinical and clinical studies.
    Swami U; Chaudhary I; Ghalib MH; Goel S
    Crit Rev Oncol Hematol; 2012 Feb; 81(2):163-84. PubMed ID: 21493087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
    Spira AI; Iannotti NO; Savin MA; Neubauer M; Gabrail NY; Yanagihara RH; Zang EA; Cole PE; Shuster D; Das A
    Clin Lung Cancer; 2012 Jan; 13(1):31-8. PubMed ID: 21862415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin mesylate in breast cancer.
    Verdaguer H; Morilla I; Urruticoechea A
    Womens Health (Lond); 2013 Nov; 9(6):517-26. PubMed ID: 24161305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin mesylate for the treatment of late-stage breast cancer.
    Gourmelon C; Frenel JS; Campone M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.